Long-term outcomes in patients with Non Small Cell Lung Cancer (NSCLC) treated by Immune Checkpoint Inhibitors (ICIs) for a minimal duration of 2 years: a cohort study in a tertiary hospital.
S. Storme (Lyon, France), L. Kiakouama (Lyon, France), M. Darrason (Lyon, France), G. Devouassoux (Lyon, France), M. Duruisseaux (Lyon, France), S. Couraud (Lyon, France)
Source: International Congress 2022 – Identification of therapeutic strategies in lung cancer
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Storme (Lyon, France), L. Kiakouama (Lyon, France), M. Darrason (Lyon, France), G. Devouassoux (Lyon, France), M. Duruisseaux (Lyon, France), S. Couraud (Lyon, France). Long-term outcomes in patients with Non Small Cell Lung Cancer (NSCLC) treated by Immune Checkpoint Inhibitors (ICIs) for a minimal duration of 2 years: a cohort study in a tertiary hospital.. 1919
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|